Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rupixiao (Shenyang Hongyao Jingcheng Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Shenyang Hongyao
- Administration
- Oral
01
Overview
Rupixiao is a traditional Chinese medicine (TCM) formula widely used in China for the treatment of breast diseases, particularly mammary gland hyperplasia (fibrocystic breast disease) and early-stage mastitis. It is composed of multiple herbal and animal-derived ingredients, including Cornu Cervi (deer horn), Herba Taraxaci (dandelion), Thallus Laminariae (kelp), Radix Trichosanthis, Caulis Spatholobi, Radix Notoginseng, and Radix Paeoniae Rubra, among others. Rupixiao is formulated to promote blood circulation, clear heat, detoxify, and soften hardness to dissipate nodules. It is manufactured by several pharmaceutical companies in China, including Shenyang Hongyao Group and Liaoning Haohushi Pharmaceuticals, and has been evaluated in clinical trials for its efficacy in reducing breast pain and nodule size.
- Brand names
- Rupixiao
- Other names
- Ru-Pi-XiaoRupixiao CapsulesRupixiao GranulesRupixiao JiaonangRupixiao KeliRupixiao PianRupixiao Tablets
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Rupixiao (Shenyang Hongyao Jingcheng Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rupixiao (Shenyang Hongyao Jingcheng Pharmaceutical).